Home/Biosimilar Atlas/Bevacizumab/Zydus bevacizumab

Zydus bevacizumab

Bevacizumab biosimilar developed by Cadila Healthcare (Zydus Lifesciences). Reference product Avastin.

Brands by market: Brand not published by CDSCO (India) · Commercial partner or holder: Zydus Lifesciences · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOMay 2017permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
BevacizumabmoleculeCadila Healthcaredeveloper1 of 7markets0trials behind it10other products, same developer7rival developers in its markets

About Zydus bevacizumab

Zydus, then Cadila Healthcare, received its bevacizumab permission in India in May 2017 for a broad set of cancers, and added a further strength in 2025. It remains an Indian product.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

MHRA

United Kingdom

Not listed by MHRA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Cadila Healthcare Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
May 2017
Application or permission
MF-097/2017; additional strength MF/BIO/25/000160
Indications as licensed
Colorectal, NSCLC, renal and other solid tumours
Presentations
100 mg/4 mL and 400 mg/16 mL
Source
S014 (CDSCO) · checked Sep 2026
EDE

United Arab Emirates

Not listed by EDE.

Other developers in the same markets

Where Zydus bevacizumab holds an approval, these are the other bevacizumab biosimilars approved in that market.

MarketRivalsDevelopers (product)
CDSCO7Biocon Biologics (Jobevne / Abevmy / Krabeva), CuraTeQ Biologics (CuraTeQ bevacizumab), Dr. Reddy's Laboratories (Dr. Reddy's bevacizumab), Enzene Biosciences (Enzene Biosciences bevacizumab), Hetero (Hetero bevacizumab), Intas Pharmaceuticals (Intas bevacizumab), Reliance Life Sciences (Reliance Life Sciences bevacizumab)

Same developer, other molecules

Other biosimilars in the Atlas developed by Zydus Lifesciences: Exemptia / Cadalimab, Nufymco, Zydus aflibercept, Zydus epoetin, Zydus follitropin alfa, Zydus peginterferon alfa-2b, Zydus pertuzumab, Zydus rituximab, Zydus teriparatide, Zydus trastuzumab.

Chronology

Sources

All bevacizumab biosimilars

Planning bevacizumab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.